Boston Scientific (BSX) Q3 FY25 earnings call

Boston Scientific delivered a strong Q3 FY25, surpassing revenue and EPS guidance, driven by exceptional performance in EP and WATCHMAN, and broad-based growth across its Cardiovascular and MedSurg segments. Despite transient headwinds in EMEA and China VBP pressures, the company raised its full-year outlook, confident in its innovative portfolio and strategic investments in high-growth adjacencies and clinical evidence to sustain above-market growth.